Monthly Archives: January 2018

Death receptor 3 (DR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, has been implicated in regulating T helper type 1 (TH)1, TH2 and TH17 responses as well as regulatory T cell and innate lymphoid cell functions during immune-med… Continue reading →

Health maintenance (HM) of patients with IBD is multifactorial and of well-established importance. However, the extent that it is practiced and whether the gastroenterologist (GI) or primary care provider (PP) would or should assume its responsibility … Continue reading →

ATIs develop in 8-60% of IBD patients1. Fully-humanized antibodies such as adalimumab and golimumab induce similar rates of immunogenicity, suggesting post-translational modifications as possible antigenic epitopes2. One consideration is sialylation, t… Continue reading →

Inflammatory Bowel Diseases (IBD) are characterized by upregulation of Interferon-gamma (IFN-γ). Recently we showed that IFN-γ blockade by a specific antibody in Dextran Sodium Sulfate (DSS)-colitis mouse model results in increased angiogenesis and r… Continue reading →

There are limited data guiding providers and payers on the most cost-effective position for vedolizumab (VDZ) in current ulcerative colitis (UC) treatment algorithms. Continue reading →

Crohn’s disease (CD) pathogenicity involves interplay of genetic and environmental factors (G+E). CD subjects and mice harboring ATG16L1 T300A, a key CD susceptibility allele, showed Paneth cell (PC) defects upon exposure to cigarette smoking, a known … Continue reading →

Bullous Pemphigus (BP) is a common acquired immunobullous disease. PB secondary to exposure to different drugs has been described. Mesalamines, Immunomodulators (Azathioprine, cylosporine), TNF alpha antagonists (Infliximab, Adalimumab and Etanercept),… Continue reading →

Integrin α4β7 expression on lymphocytes promotes their localization to the gut. A monoclonal antibody against these integrins (i.e. vedolizumab) is safe and effective treatment for inflammatory bowel disease (IBD). Given the importance of integrins o… Continue reading →

Patients with inflammatory bowel disease (IBD) on immunosuppression are at increased risk for contracting influenza. Our study was a quality improvement (QI) initiative to improve the rate of influenza vaccination and electronic medical record (EMR) do… Continue reading →

It has been suggested that vitamin D has a role in the pathogenesis and regulation of inflammatory bowel disease (IBD). However, physicians inconsistently obtain vitamin D levels in IBD patients for unclear reasons. It is speculated that the severity o… Continue reading →